Table 2 Patient and tumour characteristics

Age

Median: 59

Range: [31, 82]

Sex

Male: 136 (88.9%)

Female: 17 (11.1%)

Smoking status

Non-smoker: 68 (44.4%)

< =10 Packs/year: 25 (16.3%)

> 10–20 Packs/year: 18 (11.8%)

> 20 Packs/year: 27 (17.6%)

Unknown: 15 (9.8%)

Primary site

Tonsil: 92 (60.2%)

Base of tongue: 55 (35.9%)

Oropharynx: 1 (0.7%)

Other: 5 (3.2%)

T stage 7^th Ed/8^th Ed

T1: 47 (30.7%)

T2: 67 (43.8%)

T3: 29 (19.0%)

T4a: 9 (5.9%)

T4b: 1 (0.7%)

N stage 7^th Ed

N0: 17 (11.1%)

N1: 27 (17.6%)

N2a: 16 (10.5%)

N2b: 60 (39.2%)

N2c: 28 (18.3%)

N3: 5 (3.3%)

N stage 8^th Ed

N0: 17 (11.1%)

N1: 103 (66.9%)

N2: 28 (18.3%)

N3: 5 (3.3%)

Systemic therapy

Nil: 39 (25.4%)

Weekly Cisplatin: 85 (55.6%)

Cetuximab: 10 (6.5%)

Neoadjuvant TPF: 14 (9.2%)